New FDASIA Legislation Will Help Biotechs.
نویسنده
چکیده
The need to invest in the regulatory environment to support biotechnology innovation is urgent, says Jim Greenwood, president and CEO, Biotechnology Industry Organization.
منابع مشابه
Developing standards for breakthrough therapy designation in oncology.
In July 2012, Congress passed the Food and Drug Administration Safety and Innovation Act (FDASIA). The Advancing Breakthrough Therapies for Patients Act was incorporated into a Title of FDASIA to expedite clinical development of new, potential "breakthrough" drugs or treatments that show dramatic responses in early-phase studies. Using this regulatory pathway, once a promising new drug candidat...
متن کاملBiotechs: Show Me the Money
Money makes the biotech world go around. However, quicker circulation of that cash is driving both trends in new investment in start-ups and the approach of investors to exits. Increasingly, to get funded, new companies need to demonstrate a fast track approach that will allow the company to hit key milestone events swiftly, and those milestones may well be revenue generation events or even pro...
متن کاملThe debate on human cloning and legislative morality: notes on eugenics for an age of affluence.
My forty-five years of experience as a legislative draftsman has convinced me that an ethical or moral position will either motivate or be mentioned in legislation if such a position will help to pass the law or help to get the legislator elected. For example, housing legislation, enacted to create more public housing for working people who cannot afford to buy or rent housing produced by the m...
متن کاملUser fees and beyond--the FDA Safety and Innovation Act of 2012.
n engl j med 367;14 nejm.org october 4, 2012 1277 legislators, and patient advocates. The driving force behind the legislation was the need to reauthorize statutorily defined user fees that pharmaceutical manufacturers (since 1992) and medical-device manufacturers (since 2002) have paid when they submitted applications to the FDA for the evaluation of new products. The bill sailed through a clo...
متن کاملWill biotechnology keep the heart healthy?
Coronary heart disease kills more Americans each year than any other disease. So why have biotechs lagged in developing treatments? No quick answers, but change is coming.
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
- Biotechnology healthcare
دوره 9 4 شماره
صفحات -
تاریخ انتشار 2012